Nutritional Advice El Mondo
Objectives:
Hydroxychloroquine has been promoted for its use in treatment of COVID-19 patients based on in-vitro evidences. Therefore, this review article has been conducted.
Does hydroxychloroquine, given as add on to the standard care reduce mortality risk among COVID-19 patients?
Study design:
This review article included 6 observational studies with 251 deaths in 1,331 participants of the hydroxychloroquine arm and 363 deaths in 1,577 participants of the control arm.
In all studies, hydroxychloroquine was given as add on to the standard care and effect was compared with the standard care alone.
Results and conclusions:
The investigators found there was no difference in odds of mortality events among hydroxychloroquine and supportive care arm [OR = 1.25, 95% CI = 0.65 to 2.38, I2 = 80%].
A similar trend was observed with moderate risk of bias studies [OR = 0.95, 95% CI = 0.44 to 2.06, I2 = 85%].
The investigators found the odds of mortality were significantly higher in patients treated with hydroxychloroquine + azithromycin than supportive care alone [OR = 2.34, 95% CI = 1.63 to 3.34, I2 = 0%].
The investigators concluded a pooled analysis of recently published studies does not show additional benefit for reducing mortality in COVID-19 patients when hydroxychloroquine is given as add-on to the standard care.
Original title:
Does Adding of Hydroxychloroquine to the Standard Care Provide Any Benefit in Reducing the Mortality Among COVID-19 Patients?: A Systematic Review by Patel TK, Barvaliya M, […], Bhalla HL.
Link:
https://pubmed.ncbi.nlm.nih.gov/32519281/?from_term=meta-analysis+and+covid+19&from_sort=date&from_pos=3
Additional information of El Mondo:
Find more information/studies on coronavirus right here.